Skip to main content

Research News

  • A new study offers clues as to why a swine flu vaccine given to 6 million people in Britain was found to have triggered narcolepsy in rare cases. Scientists believe that the Pandemrix vaccine, manufactured by GlaxoSmithKline PLC (GSK), could harm a critical portion of the brain used for regulating sleep. Pandemrix was recommended by the U.K. government during the 2009-2010 swine flu outbreak, but was withdrawn after medical records showed a growing number of narcolepsy cases among those who received the vaccine.Researchers believe that the vaccine could harm a critical portion of the brain used for regulating sleep. The vaccine caused chronic illness in about one in 55,000 recipients. The study is printed in the journal Science Transitional Medicine.

  • People with blue eyes have a greater chance of becoming alcoholics, says a study. The results of the research suggest the hope of finding the roots of not only alcoholism, but also many other psychiatric illnesses. The study appeared in the American Journal of Medical Genetics: Neuropsychiatric Genetics (Part B).

  • Tel Aviv University and Harvard Medical School researchers developed a non-invasive technique that harnesses pulsed electric fields to generate growth of new skin tissue. The novel non-invasive tissue stimulation technique use microsecond-pulsed, high-voltage, non-thermal electric fields to produce scar-free skin rejuvenation. The report were published in the journal Scientific Reports.

  • A new study revealed, Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, has helped obese people lose an average of 18 pounds (eight kilograms). The findings are published in the New England Journal of Medicine.

  • A single-celled marine plankton evolved a miniature version of a multi-cellular eye, possibly to help see its prey better, according to University of British Columbia (UBC) research published today in Nature.

    [adsense:336x280:8701650588]

  • Pinaverium bromide (pinaverium), an antispasmodic, is used widely in many countries around the world, including European countries, Canada and Mexico.  However, original clinical studies on pinaverium are scarce and there has been no convincing evidence for its effectiveness and safety. As such, the U.S. Food and Drug Administration (FDA) has not approved this treatment for use in the U.S. IBS is the most common chronic (life-long in some patients) and highly recurrent gastrointestinal disorder, with an estimated worldwide prevalence of 10 to 15%.

Subscribe to Research News